Prediction: This Healthcare Stock Could Soar by 72% in 2026

And the share price appreciation could happen pretty soon.Abivax (ABVX +0.09%), a France-based biotech, saw its shares skyrocket by more than 1,740% last year after it made significant progress with its leading pipeline drug candidate, obefazimod. However, the stock may not have peaked yet.There is a reason to believe the stock could soar another 72% this year. A closer look at obefazimodObefazimod would be entering a crowded market. It is being developed to treat ulcerative colitis (UC), an area currently ...